ReviewHepatology (Baltimore, Md.)2025
Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease.
Review in Hepatology (Baltimore, Md.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Bile acid metabolites and carotid intima media thickness in the Chronic Kidney Disease in Children (CKiD) study.Pediatric nephrology (Berlin, Germany) · 2026Article
- Segment-Specific Gut Microbiome and Bile Acid Profiles in Grazing and Stall-Fed Yaks.Microorganisms · 2026Article
- The Polysaccharides fromNutrients · 2026Article
- Vaptans: A Narrative Review of Pharmacokinetics, Pharmacogenetics, and Clinical Applications.Cells · 2026Review
- Lysimachiae Herba Modulates FXR to Alleviate Cholestatic Liver Injury: Insights from Serum Pharmacochemistry and Experimental Validation.Current issues in molecular biology · 2026Article
- Correspondence to editorial on "Gut microbiota-mediated berberine metabolism ameliorates cholestatic liver disease by suppressing 5-hydroxytryptamine production".Clinical and molecular hepatology · 2026Article
- Ecology and engineering to modify the bile acid output of a defined microbial community.bioRxiv : the preprint server for biology · 2026Article
- Post-Translational Modifications of NTCP: A Regulatory Nexus for Bile Acid Transport and HBV Entry.Biomedicines · 2026Review
- Dysbiosis in the Gut-Liver Axis Is Associated With Low Bone Mass During Murine Cholestasis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Review
- The secretory protein, CLCF1, improves cholestatic liver disease by inhibiting hepatic bile acid synthesis and promoting bile acid excretion.Communications biology · 2026Article
- Bile acid signaling: from dynamic pool composition to inter-organ communication.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Progress in our understanding of the molecular basis of bile acid (BA) transport in the liver, bile ducts, intestine, and kidney has not only advanced our understanding of the pathophysiology of cholestasis and metabolic dysfunction-associated liver disease but also led to novel therapeutic approaches targeting BA transport and signaling within the entero-nephro-hepatic circulation. This includes BA transport modulators such as inhibitors of the apical BA-transport system in the terminal ileum and proximal renal tubule (IBAT/ASBT inhibitors) and basolateral (sinusoidal) BA uptake in hepatocytes (NTCP inhibitors). In addition to altering membrane transporter function by targeting IBAT/ASBT and NTCP, there is an array of potentially additive therapeutic approaches which include receptor agonists acting via nuclear receptor (FXR, PPAR)-mediated transcriptional modification of BA synthesis and transport genes and BA analogs such as norucholic acid (previously known as norUDCA) that undergo cholehepatic shunting. This article reviews established and emerging molecular and clinical rationales for therapeutic targeting of BA circulation and signaling in liver diseases with a specific focus on cholestatic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.